Trigger for Group A Streptococcal M1T1 Invasive Disease by Cole, J. N. et al.
University of Wollongong 
Research Online 
Faculty of Science - Papers (Archive) Faculty of Science, Medicine and Health 
1-8-2006 
Trigger for Group A Streptococcal M1T1 Invasive Disease 
J. N. Cole 
University of Wollongong, jcole@uow.edu.au 
Jason D. McArthur 
University of Wollongong, jasonm@uow.edu.au 
F. C. McKay 
University of Wollongong 
Martina L. Sanderson-Smith 
University of Wollongong, martina@uow.edu.au 
Amanda J. Cork 
University of Wollongong, acork@uow.edu.au 
See next page for additional authors 
Follow this and additional works at: https://ro.uow.edu.au/scipapers 
 Part of the Life Sciences Commons, Physical Sciences and Mathematics Commons, and the Social 
and Behavioral Sciences Commons 
Recommended Citation 
Cole, J. N.; McArthur, Jason D.; McKay, F. C.; Sanderson-Smith, Martina L.; Cork, Amanda J.; Ranson, 
Marie; Rohde, M.; Itzek, A.; Sun, H.; Ginsburg, D.; Kotb, M.; Nizet, V.; Chhatwal, G. S.; and Walker, Mark J.: 
Trigger for Group A Streptococcal M1T1 Invasive Disease 2006. 
https://ro.uow.edu.au/scipapers/100 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 
Trigger for Group A Streptococcal M1T1 Invasive Disease 
Abstract 
The globally disseminated Streptococcus pyogenes M1T1 clone causes a number of highly invasive 
human diseases. The transition from local to systemic infection occurs by an unknown mechanism; 
however invasive M1T1 clinical isolates are known to express significantly less cysteine protease SpeB 
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The globally disseminated Streptococcus pyogenes M1T1 clone causes a number of highly 
invasive human diseases. The transition from local to systemic infection occurs by an 
unknown mechanism; however invasive M1T1 clinical isolates are known to express 
significantly less cysteine protease SpeB than M1T1 isolates from local infections. Here, 
we show that in comparison to the M1T1 strain 5448, the isogenic mutant ∆speB 
accumulated 75-fold more human plasmin activity on the bacterial surface following 
incubation in human plasma. Human plasminogen was an absolute requirement for M1T1 
strain 5448 virulence following subcutaneous infection of humanized plasminogen 
transgenic mice. S. pyogenes M1T1 isolates from the blood of infected humanized 
plasminogen transgenic mice expressed reduced levels of SpeB in comparison with the 
parental 5448 used as inoculum. We propose that the human plasminogen system plays a 
critical role in group A streptococcal M1T1 systemic disease initiation. SpeB is required for 
S. pyogenes M1T1 survival at the site of local infection, however, SpeB also disrupts the 
interaction of S. pyogenes M1T1 with the human plasminogen activation system. Loss of 
SpeB activity in a sub-population of S. pyogenes M1T1 at the site of infection results in 
accumulation of surface plasmin activity thus triggering systemic spread. 
 






Epidemic invasive group A Streptococcus (GAS, S. pyogenes) disease in the Western 
World since the mid-1980s has been paralleled by the emergence of a globally 
disseminated serotype M1T1 GAS clone (1). This M1T1 clone is associated with life-
threatening infections such as necrotizing fasciitis and streptococcal toxic shock syndrome 
(2), whilst also causing uncomplicated infections in other patients (3). The mechanism that 
triggers the transition from local to invasive infection by GAS M1T1 is unknown, however 
epidemiologic studies have documented an inverse relationship between human invasive 
disease and the expression of the streptococcal pyrogenic exotoxin B (SpeB) (4). SpeB is a 
secreted cysteine protease initially expressed as a 40-kDa zymogen which is then converted 
to its 28-kDa active form by autocatalytic truncation (5). SpeB is known to cleave host 
proteins including extracellular matrix components, cytokine precursors, immunoglobulins 
and antimicrobial peptides (1, 6, 7), and has been shown to play an important role in 
establishing localized skin infections (8). SpeB also degrades GAS virulence factors 
including the cell wall-associated fibrinogen-binding anti-phagocytic M1 protein (9, 10), 
various superantigens (11, 12), and the secreted plasminogen activator streptokinase (13). 
 
The capacity of GAS to assemble on its surface a trimolecular complex containing 
streptokinase, fibrinogen, and plasminogen has been correlated with a propensity for 
invasive infection (14). GAS is a highly specific human pathogen and the streptokinase 
produced by this organism displays a much greater affinity for human plasminogen than 
mouse plasminogen (15). A major advance in the understanding of GAS pathogenesis was 
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attained by Sun et al. (15) who established a humanized plasminogen transgenic mouse 
model. These researchers demonstrated that streptokinase and the activation of 
plasminogen to plasmin is critical for GAS dissemination in vivo, leading to the proposal 
that human plasminogen is hijacked for use as a virulence factor by GAS (15, 16). In this 
study, we utilize the representative wild-type (WT) clonal M1T1 strain 5448 and the 
precise, in-frame allelic replacement mutant ∆speB (11, 17) to investigate the interplay 


















MATERIALS AND METHODS 
 
Strains, media and culture conditions  
S. pyogenes strain 5448 (M1T1) and the isogenic ∆speB mutant have been described 
previously (12). All S. pyogenes strains were routinely cultured at 37°C on horse-blood 
agar (BioMérieux) or in static liquid cultures of Todd-Hewitt broth (Difco) supplemented 
with 1% (w/v) yeast extract (THBY medium). When required, SpeB was inactivated by 
growth in the presence of cysteine protease inhibitor E64 (N-[N-(L-3-transcarboxyirane-2-
carbonyl)-L-Leucyl]-agmatine) (Sigma) at a final concentration of 28 μM. 
 
Hyaluronic acid capsule determination 
Overnight cultures of S. pyogenes were diluted 1:10 in fresh THBY media and grown to an 
optical density at 600 nm (OD600) of 0.5-0.6. The hyaluronic acid capsule was extracted and 
quantified by the Stains-all method (18). 
 
Preparation of culture supernatant proteins 
An overnight culture of S. pyogenes was diluted 1:10 in fresh THBY medium and 
incubated at 37°C to late stationary phase (approx. 16 h). The culture supernatant was 
harvested by centrifugation at 8,000 × g for 20 min at 4°C and filter sterilized through a 
0.22 µm filter (Millipore) for use in SpeB activity assays. For sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) analysis, equal volumes of cell-free 
supernatant and 10% (v/v) trichloroacetic acid were mixed and incubated on ice for 1 h. 
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Following centrifugation at 15,000 × g for 20 min at 4°C, the pellet was washed with ice-
cold 100% ethanol and centrifuged at 15,000 × g for 15 min at 4°C. The ethanol was 
removed by aspiration, the pellet air-dried for 30 min and resuspended in 1 ml of 100 mM 
Tris-HCl (pH 7.6). 
 
SpeB activity assays 
Cysteine protease SpeB activity in S. pyogenes culture supernatants was determined 
according to the method of Hytönen et al. (19). To examine SpeB activity of large numbers 
of S. pyogenes colonies, the Columbia skim milk plate based assay was used according to 
the method of Ashbaugh et al. (20). 
 
Immunogold electron microscopy 
S. pyogenes were fixed with 0.2% glutaraldehyde and 0.5% formaldehyde for 1 h on ice, 
washed with cacodylate buffer (0.1 M cacodylate, 0.9 M sucrose, 0.01 M MgCl2, 0.01 M 
CaCl2; pH 6.9) containing 10 mM glycine, and dehydrated with ethanol following the 
progressive lowering of temperature protocol (10%, 30% ethanol on ice; 50% ethanol at –
20°C; 70, 90, 100% ethanol at –30°C; each step for 30 min). Samples were infiltrated with 
the Lowicryl® resin K4M over 3 days before polymerization at –30°C with UV light (366 
nm) for 2 days and 1 day at room temperature. Ultrathin sections were collected with 
formvar-coated cover-slips and incubated with SpeB specific IgG antibodies (75 µg/ml, 10 
h at 4°C), washed with PBS and bound antibodies were made visible with protein A/G 
coated gold-particles (10 nm or 15 nm in size). Samples were counter-stained with uranyl 
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acetate for 1 min and air-dried before examination in a Zeiss transmission electron 
microscope EM910 at an acceleration voltage of 80 kV. 
 
Plasminogen binding and cell surface plasmin activity 
The binding of 125I-plasminogen was measured as reported elsewhere (14). Approximately 
70 ng of 125I-plasminogen was added to 250 μl of cell suspension and incubated at room 
temperature for 45 min. The cells were harvested by centrifugation, the supernatant 
carefully aspirated and pellet-associated radioactivity measured using an automatic gamma 
counter (Wallac). The results were expressed as a percentage of input radioactivity. All 
measurements were determined in triplicate. 
 
Plasmin acquisition in human plasma by S. pyogenes isolates was determined essentially as 
described previously (21). Frozen plasma was purchased from the Red Cross Blood Bank 
(Sydney, NSW, Australia), defrosted on ice and pooled. Aliquots of pooled plasma were 
depleted of plasminogen by incubation at 4°C on ice with excess lysine-sepharose® 4B for 
1-2 h with gentle agitation. The extent of plasminogen depletion and the plasmin activity of 
plasma was determined by chromogenic assay with Spectrozyme® PL (American 
Diagnostics Inc.) in the presence and absence of streptokinase, and by western blot using a 
polyclonal rabbit anti-human plasminogen antibody (Calbiochem).  
 
GAS were cultured overnight as stationary cultures in 25 ml THY inoculated with 1 colony.  
GAS were pelleted by centrifugation at 800 × g, washed in 50 ml of PBS, pH 7.4 
 8
prewarmed to 37°C, and resuspended to OD600 = 0.7 (corresponding to log phase, in which 
streptokinase secretion is induced). A 2 ml aliquot of this suspension was pelleted as above, 
and resuspended in an equal volume of 100% plasma or plasminogen-depleted plasma at 
37°C. GAS were incubated in plasma for 3 h at 37°C, pelleted by centrifugation and 
washed twice with 1 volume of ice-cold 0.01 M EDTA, 0.1% (w/v) gelatin in PBS, pH 7.4. 
GAS were resuspended in 0.1% (w/v) gelatin in PBS, pH 7.4 to OD600 = 0.75. Aliquots 
(100 µl) of this suspension were incubated in triplicate in the presence and absence of 20 µl 
Spectrozyme® PL, 2.5 mM at 37°C for 60 min in a 96-well plate. The reaction was 
quenched with 80 µl of 1.75 M acetic acid, the plates centrifuged at 800 × g and A405 of 
supernatants determined. 
 
Plasmin activity was determined as the difference between A405 in the presence and absence 
of substrate, thus accounting for differences in the sedimentation efficiency of GAS 
isolates. Each isolate was assayed in at least 2 independent experiments. Plasmin 
equivalents and the linear range of the assay (A405 = 0 – 0.6) were determined using a 
standard curve of purified plasmin  (Roche Diagnostics, GmbH, Mannheim, Germany). 
 
Extraction of cell wall-associated proteins 
Mutanolysin cell-wall extracts were prepared from stationary phase cultures of S. pyogenes 





Affinity purified rabbit anti-SpeB IgG was purchased from Toxin Technology Inc., 
Sarasota, Florida, USA. Polyclonal rabbit antibodies were raised against purified 
recombinant S. pyogenes streptococcal enolase (SEN) and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). A rabbit polyclonal antiserum was raised against Lancefield 
group C streptokinase (Sigma), which shares >90% identity with the streptokinase (Ska) 
protein of S. pyogenes. All rabbit immunizations were performed according to the method 
of Gillen et al. (23). The production of mouse polyclonal antiserum against M1 protein is 
described elsewhere (24). 
 
Western blot analysis 
SDS-PAGE was performed according to the method of Laemmli (25). Cell wall extracts or 
culture supernatant proteins were transferred to nitrocellulose membrane at 100 V for 1 h 
using the Mini Trans-Blot® (Bio-Rad) (26). The membranes were blocked in a solution of 
5% (w/v) skim milk (Difco) in phosphate buffered saline (PBS; 137 mM NaCl, 2.7 mM 
KCl, 7.9 mM Na2HPO4, 1.5 mM KH2PO4; pH 7.4) for 1 h at room temperature. After a 10 
min wash with PBS, the membranes were incubated for 2 h with primary antibody diluted 
1:1,000 in PBS. Following three washes for 10 min each with PBS, the membranes were 
incubated for 1 h with a 1:1,000 dilution of goat anti-rabbit IgG HRP conjugate (Bio-Rad) 
for SpeB, Ska, SEN and GAPDH blots, or a 1:1,000 dilution of goat anti-mouse IgG HRP 
conjugate (Bio-Rad) for M1 protein blots. Excess secondary antibody was removed by 
three PBS washes for 10 min each and all blots developed in a solution of 100 mM Tris-




Five micrograms of SpeB protease (Toxin Technology Inc.) was mixed with 5 μg of 
purified human plasminogen or fibrinogen (14), adjusted to final volume of 25 μl with PBS 
(pH 7.4) and incubated at 37°C for 3 h. Cleavage of substrate protein was determined by 
SDS-PAGE analysis. Positive controls containing 5 μg SpeB and 25 μg β-casein (Sigma) 
were used in all assays. Negative controls containing protease or substrate only were also 
included. 
 
Streptococcal infection model 
AlbPLG1 transgenic mice (Tg+) (27) heterozygous for the human plasminogen transgene 
were backcrossed greater than N6 with C57BL/J6 mice (Animal Resources Centre, Perth, 
Australia). Non-transgenic (Tg-) littermates were used as controls in all experiments. 
Streptococcal strains used for inocula were harvested at mid-log phase (OD600 approx. 0.5). 
Bacteria were washed with an equal volume of sterile 0.7% saline and diluted to the 
required inoculum. The number of viable bacteria present was determined by counting 
colony forming units (CFU) after plating a dilution series onto blood agar plates 
(BioMérieux). Groups of 10 Tg+ mice and Tg- littermates were infected with either 2.8 × 
108 CFU (5448) or 1.35 × 108 CFU (∆speB mutant) via a subcutaneous injection into a 
shaved region of the right flank of each mouse. Mortality was recorded over 14 days. 
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For experiments examining the dissemination of streptococci during infection, a separate 
cohort of Tg+ mice was inoculated subcutaneously.  Wild type 5448 was inoculated using 
1.58 × 109 CFU (n = 4; 1 mouse succumbed to infection on day 2) and 1.49 × 108 CFU (n = 
1). The 5448 mutant ∆speB was inoculated using 1.71 × 109 CFU (mutant; n = 4; 1 mouse 
succumbed to infection on day 2) and 4.5 × 107 CFU (n = 1). On day 3 post-infection, mice 
were sacrificed by CO2 asphyxiation and representative bacteria were isolated from the site 
of initial infection and bacterial loads present in the bloodstream were determined by 
plating serial dilutions onto blood agar. All experiments were conducted according to the 
Guidelines for the Care and Use of Laboratory Animals (National Health and Medical 




Average capsular hyaluronic acid, SpeB activity and plasminogen binding for 5448 and 
∆speB were compared using the two-tailed unpaired t test. Cell surface plasmin activity 
levels were evaluated using the Welch ANOVA (assuming unequal variances). Differences 
in survival of Tg+ and Tg- mice infected with 5448 and ∆speB were determined by the log-
rank test. Mean bacterial loads in the bloodstream (log10 CFU) of Tg+ mice infected with 
5448 or ∆speB were compared using the two-tailed unpaired t test. The t and log-rank tests 
were performed using GraphPad Prism version 4.02 (GraphPad Software Inc., San Diego, 





Characterization of M1T1 strain 5448 and ∆speB 
Both WT and isogenic ∆speB mutant strains expressed identical amounts of hyaluronic acid 
capsule (Fig. 1a), excluding a pleiotropic mutation that confounded earlier studies of SpeB 
in GAS pathogenesis (20). Secreted cysteine protease activity was undetectable in the 
∆speB mutant (P ≤ 0.05; Fig. 1b), and SpeB zymogen was only detected at the cell wall 
ExPortal microdomain (28) of the parent M1T1 strain (Fig. 1c). Nonetheless, both WT and 
∆speB mutant bound equivalent amounts of purified human plasminogen (Fig. 1d). These 
data indicate that, like the GAS M5 strain characterized by Rosch and Caparon (28), the 
M1T1 clone also secretes SpeB zymogen via the ExPortal microdomain. The presence or 
absence of SpeB does not effect the capacity of M1T1 GAS to bind purified human 
plasminogen, suggesting that the surface plasminogen receptors α-enolase (SEN) (29) and 
GAPDH (30) are not disabled by SpeB proteolysis. However, in comparison to the WT 
strain, the isogenic ∆speB mutant accumulated 75-fold higher levels of human plasmin 
activity on the bacterial surface following incubation in human plasma for 3 h at 37oC (P ≤ 
0.05; Fig. 1e). 
 
Analysis of plasminogen activation system components 
In order to elucidate the underlying reason(s) for the enhanced capacity of the cysteine 
protease-deficient GAS strain to accumulate surface plasmin activity, we compared WT 
and ∆speB mutant strains for the expression of cell wall-associated plasminogen and 
 13
fibrinogen receptors and for secretion of streptokinase. Active 28-kDa SpeB was identified 
only in supernatants of the WT strain; with addition of the SpeB inhibitor E64 just the 40-
kDa SpeB zymogen form was detected (Fig. 2a). Streptokinase was only present in 
supernatants of the ∆speB mutant or the WT parent strain grown in the presence of E64 
(Fig. 2a). The fibrinogen-binding M1 protein was found in cell wall extracts only in the 
absence of SpeB activity, whereas plasminogen receptors SEN and GAPDH were detected 
in cell wall extracts of both WT and ∆speB mutant (Fig. 2a). SpeB was also observed to 
degrade plasminogen directly, as well as fibrinogen, which forms a trimolecular complex 
with streptokinase and plasminogen bound to the GAS surface (14, 31) (Fig. 2b). Thus, 
SpeB interferes with the accumulation of GAS surface bound plasmin activity by cleaving 
four critical factors: plasminogen, the plasminogen activator streptokinase, fibrinogen and 
the fibrinogen-binding M1 protein (16). 
 
Infection of humanized plasminogen transgenic mice 
We next took advantage of heterozygous AlbPLG1 mice that express a human plasminogen 
transgene (Tg+) (15) and littermate C57BL/J6 control mice (Tg-) to examine the virulence 
of WT M1T1 GAS and the isogenic ∆speB mutant in a subcutaneous infection model. Only 
through use of this transgenic mouse line can one investigate the interaction of GAS with 
the plasminogen activation system, since this interaction is highly specific for human 
plasminogen (15, 16). In comparison to infection of non-transgenic control mice, the 
virulence of WT M1T1 strain was significantly increased in Tg+ mice (P ≤ 0.05; 10% vs. 
80% mortality) (Fig. 3a). This result indicates that the human plasminogen system plays a 
crucial role in the ability of M1T1 GAS to initiate a lethal systemic infection.  In 
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comparison to the WT GAS parent strain, the isogenic ∆speB mutant was attenuated for 
virulence in the Tg+ plasminogen-humanized mice (P ≤ 0.05; 80% vs. 20% mortality) (Fig. 
3a, b). Additionally, in comparison to GAS strain 5448, 72 h post-infection of Tg+ mice the 
isogenic ∆speB mutant displayed significantly fewer bacterial counts in the blood (P ≤ 
0.05; Fig. 3c). These data support a role for SpeB in GAS survival at the site of local 
infection in the skin, as proposed by Svensson et al. (8), and suggested this difference may 
translate into an overall decreased lethality upon challenge with the ∆speB mutant.   
 
To further examine the interaction between the human plasminogen system and GAS 
cysteine protease SpeB, we examined the SpeB expression status of WT GAS isolated from 
the blood of the infected plasminogen-humanized Tg+ mice. The WT GAS used in the 
initial challenge uniformly expressed high levels of cysteine protease activity (100% of 
inoculum colonies tested; n = 100). Bacteria isolated from the subcutaneous site of 
infection expressed a mixed phenotype (74%, 66%, 63% and 31% of lesion recovered 
colonies SpeB-negative from 4 subcutaneously inoculated Tg+ mice). Bacteria recovered 
from the blood unvaryingly demonstrated very low SpeB activity (100% of blood isolated 
colonies examined SpeB-negative) (Fig. 3d). This finding is consistent with the 
epidemiologic observation that M1T1 clinical isolates from human invasive disease express 







The mechanism utilized by GAS to switch from localized to systemic infection is presently 
unknown. However, subversion of the host plasminogen activation system is thought to 
play a key role (15, 16). In this study, we have shown that the absence of cysteine protease 
SpeB activity is required for the accumulation of plasmin activity on the cell surface of 
M1T1 GAS. In a humanized plasminogen transgenic mouse model, the loss of SpeB 
activity at the site of infection triggers the systemic dissemination of M1T1 GAS in vivo. 
These data support the proposal that human plasminogen plays a critical role in the 
initiation of GAS invasive disease. 
 
Plasminogen is the proenzyme form of plasmin, a blood clot-dissolving serine protease 
which degrades extracellular matrix components and activates matrix metalloproteases 
(32). In S. pyogenes, two distinct pathways have been identified for the binding of 
plasminogen to the cell surface. The direct pathway is mediated by the plasminogen-
binding GAS M-like protein (PAM) (33), streptococcal enolase (SEN) (29) and GAPDH 
(29, 34). Indirect plasminogen-binding requires the formation of a trimolecular complex 
between plasminogen, streptokinase and fibrinogen, which is bound to the GAS cell surface 
via plasminogen or fibrinogen receptors (14, 31, 35). Human plasminogen is converted to 
plasmin by the plasminogen activators urokinase (uPA) and tissue-type plasminogen 
activator (tPA), or by secreted microbial activators including the GAS virulence factor 
streptokinase (36). Here, we demonstrate that the presence of SpeB does not interfere with 
the binding of plasminogen to the GAS cell surface. However, SpeB degrades four key 
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factors required for the accumulation of surface plasmin activity on the GAS surface: 
plasminogen, streptokinase, fibrinogen, and the fibrinogen-binding M1 protein.  
 
Utilizing a speB-negative mutant and a humanized in vivo model for impetigo in which 
neonatal foreskin was engrafted onto the hind flanks of CB-17 scid mice, Svensson et al. 
(8) determined that SpeB protease plays a critical role in the establishment of host tissue 
tropism by GAS. Our accumulated data suggest that SpeB, while contributing to localized 
infection, simultaneously mitigates the potential interaction of M1T1 GAS with the human 
plasminogen activation system. The ablation of SpeB expression in WT M1T1 GAS in the 
blood of plasminogen-humanized Tg+ mice indicates that the loss of SpeB activity in a sub-
population of bacteria occurs at the site of infection, allowing accumulation of surface 
plasmin activity. This sub-population thus gain enhanced invasive propensity, favoring 
transition of GAS from the site of infection to the blood. In our model, vascular leakage 
induced by M protein complexing with fibrinogen to activate heparin binding protein 
release from neutrophils, may provide a source of plasminogen at the site of infection (37) 
(Fig. 4). The subpopulation of GAS undergoing a phase shift to eliminate SpeB expression 
gain not only the capacity to accumulate cell surface plasmin activity and spread 
systemically, but also elaborate greater levels of superantigens (12), the causative agents of 
streptococcal toxic shock. 
 
The expression of the streptococcal cysteine protease SpeB and human invasive disease 
severity are inversely related in M1T1 clonal isolates (4). The model we propose for GAS 
human systemic disease initiation accounts for this previously perplexing clinical 
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observation and describes a mechanism by which systemic disease initiation occurs. The 
elucidation of the mechanism by which GAS causes human invasive disease will inform 
























We thank K. S. Sriprakash (Queensland Institute of Medical Research, Queensland, 
Australia) for providing M1 protein antiserum. J. N. Cole, M. L. Sanderson-Smith and A. J. 
Cork are the recipients of an Australian Postgraduate Award. D. Ginsburg is a Howard 
Hughes Medical Institute Investigator. This work was supported by the National Health and 




















1. Cunningham, M. W. (2000) Pathogenesis of group A streptococcal infections. Clin. 
Microbiol. Rev. 13, 470-511 
2. Stevens, D. L. (1992) Invasive group A Streptococcus infections. Clin. Infect. Dis. 
14, 2-11 
3. Johnson, D. R., Wotton, J. T., Shet, A., and Kaplan, E. L. (2002) A comparison of 
group A streptococci from invasive and uncomplicated infections: Are virulent clones 
responsible for serious streptococcal infections? J. Infect. Dis. 185, 1586-1595 
4. Kansal, R. G., McGeer, A., Low, D. E., Norrby-Teglund, A., and Kotb, M. (2000) 
Inverse relation between disease severity and expression of the streptococcal cysteine 
protease, SpeB, among clonal M1T1 isolates recovered from invasive group A 
streptococcal infection cases. Infect. Immun. 68, 6362-6369 
5. Musser, J., Stockbauer, K., Kapur, V., and Rudgers, G. (1996) Substitution of 
cysteine 192 in a highly conserved Streptococcus pyogenes extracellular cysteine 
protease (interleukin 1β convertase) alters proteolytic activity and ablates zymogen 
processing. Infect. Immun. 64, 1913-1917 
6. Hynes, W. (2004) Virulence factors of the group A streptococci and genes that 
regulate their expression. Front. Biosci. 9, 3399-3433 
7. Nyberg, P., Rasmussen, M., and Björck, L. (2004) α2-Macroglobulin-proteinase 
complexes protect Streptococcus pyogenes from killing by the antimicrobial peptide 
LL-37. J. Biol. Chem. 279, 52820-52823 
 20
8. Svensson, M. D., Scaramuzzino, D. A., Sjöbring, U., Olsen, A., Frank, C., and 
Bessen, D. E. (2000) Role for a secreted cysteine proteinase in the establishment of 
host tissue tropism by group A streptococci. Mol. Microbiol. 38, 242-253 
9. Ringdahl, U., Svensson, H. G., Kotarsky, H., Gustafsson, M., Weineisen, M., and 
Sjöbring, U. (2000) A role for the fibrinogen-binding regions of streptococcal M 
proteins in phagocytosis resistance. Mol. Microbiol. 37, 1318-1326 
10. Raeder, R., Woischnik, M., Podbielski, A., and Boyle, M. D. (1998) A secreted 
streptococcal cysteine protease can cleave a surface-expressed M1 protein and alter 
the immunoglobulin binding properties. Res. Microbiol. 149, 539-548 
11. Kansal, R. G., Nizet, V., Jeng, A., Chuang, W. J., and Kotb, M. (2003) Selective 
modulation of superantigen-induced responses by streptococcal cysteine protease. J. 
Infect. Dis. 187, 398-407 
12. Aziz, R. K., Pabst, M. J., Jeng, A., Kansal, R., Low, D. E., Nizet, V., and Kotb, M. 
(2004) Invasive M1T1 group A Streptococcus undergoes a phase-shift in vivo to 
prevent proteolytic degradation of multiple virulence factors by SpeB. Mol. 
Microbiol. 51, 123-134 
13. Rezcallah, M. S., Boyle, M. D., and Sledjeski, D. D. (2004) Mouse skin passage of 
Streptococcus pyogenes results in increased streptokinase expression and activity. 
Microbiology 150, 365-371 
14. McKay, F. C., McArthur, J. D., Sanderson-Smith, M. L., Gardam, S., Currie, B. J., 
Sriprakash, K. S., Fagan, P. K., Towers, R. J., Batzloff, M. R., Chhatwal, G. S., 
Ranson, M., and Walker, M. J. (2004) Plasminogen binding by group A streptococcal 
 21
isolates from a region of hyperendemicity for streptococcal skin infection and a high 
incidence of invasive infection. Infect. Immun. 72, 364-370 
15. Sun, H., Ringdahl, U., Homeister, J. W., Fay, W. P., Engleberg, N. C., Yang, A. Y., 
Rozek, L. S., Wang, X., Sjöbring, U., and Ginsburg, D. (2004) Plasminogen is a 
critical host pathogenicity factor for group A streptococcal infection. Science 305, 
1283-1286 
16. Walker, M. J., McArthur, J. D., McKay, F., and Ranson, M. (2005) Is plasminogen 
deployed as a Streptococcus pyogenes virulence factor? Trends. Microbiol. 13, 308-
313 
17. Kazmi, S. U., Kansal, R., Aziz, R. K., Hooshdaran, M., Norrby-Teglund, A., Low, D. 
E., Halim, A. B., and Kotb, M. (2001) Reciprocal, temporal expression of SpeA and 
SpeB by invasive M1T1 group A streptococcal isolates in vivo. Infect. Immun. 69, 
4988-4995 
18. Schrager, H. M., Rheinwald, J. G., and Wessels, M. R. (1996) Hyaluronic acid 
capsule and the role of streptococcal entry into keratinocytes in invasive skin 
infection. J. Clin. Invest. 98, 1954-1958 
19. Hytönen, J., Haataja, S., Gerlach, D., Podbielski, A., and Finne, J. (2001) The SpeB 
virulence factor of Streptococcus pyogenes, a multifunctional secreted and cell 
surface molecule with strepadhesin, laminin-binding and cysteine protease activity. 
Mol. Microbiol. 39, 512-519 
20. Ashbaugh, C. D., Warren, H. B., Carey, V. J., and Wessels, M. R. (1998) Molecular 
analysis of the role of the group A streptococcal cysteine protease, hyaluronic acid 
 22
capsule, and M protein in a murine model of human invasive soft-tissue infection. J. 
Clin. Invest. 102, 550-560 
21. Wang, H., Lottenberg, R., and Boyle, M. D. (1994) Analysis of plasmin(ogen) 
acquisition by clinical isolates of group A streptococci incubated in human plasma. J. 
Infect. Dis. 169, 143-149 
22. Cole, J. N., Ramirez, R. D., Currie, B. J., Cordwell, S. J., Djordjevic, S. P., and 
Walker, M. J. (2005) Surface analyses and immune reactivities of major cell wall-
associated proteins of group A Streptococcus. Infect. Immun. 73, 3137-3146 
23. Gillen, C. M., Towers, R. J., McMillan, D. J., Delvecchio, A., Sriprakash, K. S., 
Currie, B., Kreikemeyer, B., Chhatwal, G. S., and Walker, M. J. (2002) 
Immunological response mounted by Aboriginal Australians living in the Northern 
Territory of Australia against Streptococcus pyogenes serum opacity factor. 
Microbiology 148, 169-178 
24. McMillan, D. J., Davies, M. R., Good, M. F., and Sriprakash, K. S. (2004) Immune 
response to superoxide dismutase in group A streptococcal infection. FEMS Immunol. 
Med. Microbiol. 40, 249-256 
25. Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the 
head of bacteriophage T4. Nature 227, 680-685 
26. Burnette, W. N. (1981) Western blotting: Electrophoretic transfer of proteins from 
sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and 
radiographic detection with antibody and radioiodinated protein A. Anal. Biochem. 
112, 195-203 
 23
27. Sun, H., Ringdahl, U., Homeister, J. W., Fay, W. P., Engleberg, N. C., Yang, A. Y., 
Rozek, L. S., Wang, X., Sjobring, U., and Ginsburg, D. (2004) Plasminogen is a 
critical host pathogenicity factor for group A streptococcal infection. Science 305, 
1283-1286 
28. Rosch, J., and Caparon, M. (2004) A microdomain for protein secretion in Gram-
positive bacteria. Science 304, 1513-1515 
29. Pancholi, V., and Fischetti, V. A. (1998) α-Enolase, a novel strong plasmin(ogen) 
binding protein on the surface of pathogenic streptococci. J. Biol. Chem. 273, 14503-
14515 
30. Pancholi, V., and Fischetti, V. (1992) A major surface protein on group A 
streptococci is a glyceraldehyde-3-phosphate-dehydrogenase with multiple binding 
activity. J. Exp. Med. 176, 415-426 
31. Wang, H., Lottenberg, R., and Boyle, M. D. (1995) A role for fibrinogen in the 
streptokinase-dependent acquisition of plasmin(ogen) by group A streptococci. J. 
Infect. Dis. 171, 85-92 
32. Werb, Z. (1997) ECM and cell surface proteolysis: regulating cellular ecology. Cell 
91, 439-442 
33. Berge, A., and Sjöbring, U. (1993) PAM, a novel plasminogen-binding protein from 
Streptococcus pyogenes. J. Biol. Chem. 268, 25417-25424 
34. Lottenberg, R., Broder, C. C., Boyle, M. D., Kain, S. J., Schroeder, B. L., and Curtiss, 
R., 3rd (1992) Cloning, sequence analysis, and expression in Escherichia coli of a 
streptococcal plasmin receptor. J. Bacteriol. 174, 5204-5210 
 24
35. Wang, H., Lottenberg, R., and Boyle, M. D. (1995) Analysis of the interaction of 
group A streptococci with fibrinogen, streptokinase and plasminogen. Microb. 
Pathog. 18, 153-166 
36. Boyle, M. D., and Lottenberg, R. (1997) Plasminogen activation by invasive human 
pathogens. Thromb. Haemost. 77, 1-10 
37. Herwald, H., Cramer, H., Morgelin, M., Russell, W., Sollenberg, U., Norrby-
Teglund, A., Flodgaard, H., Lindbom, L., and Björck, L. (2004) M protein, a classical 
bacterial virulence determinant, forms complexes with fibrinogen that induce vascular 






























Figure 1. In vitro characterization of M1T1 S. pyogenes strain 5448 (WT) and the isogenic 
∆speB mutant. (a) 5448 and the ∆speB mutant express equivalent amounts of capsular 
hyaluronic acid (mean ± s.d.). (b) Secreted SpeB protease activity (mean ± s.d.) is 
abolished in the ∆speB mutant compared with 5448. (c) Electron microscopic analyses 
detected SpeB zymogen at the ExPortal microdomain of 5448, but not ∆speB (data not 
shown). (d) Equivalent amounts of purified human 125I-labelled plasminogen (mean ± s.d.) 
are bound by 5448 and ∆speB. (e) The ∆speB mutant cell surface accrues a 75-fold higher 













Figure 2. Western blot analysis and in vitro SpeB protease assays. (a) Blots of secreted 
(SpeB, Ska and SEN) or cell wall-associated proteins (M1 and GAPDH) harvested in the 
presence or absence of SpeB inhibitor E64 for 5448 (WT) and the isogenic ∆speB mutant. 
Lane 1, 5448 culture supernatant or cell wall (-E64); lane 2, ∆speB culture supernatant or 
cell wall (-E64); lane 3, 5448 culture supernatant or cell wall (+E64); lane 4, ∆speB culture 
supernatant or cell wall (+E64). Filled arrowheads indicate major immunoreactive bands. 
(b) SpeB protease degrades human plasminogen and fibrinogen, which play a key role in 
the accumulation of surface-bound plasmin activity by S. pyogenes. Lane 1, SpeB; lane 2, 
β-casein; lane 3, SpeB and β-casein (positive control); lane 4, plasminogen; lane 5, SpeB 
and plasminogen; lane 6, fibrinogen; lane 7, SpeB and fibrinogen. Molecular mass markers 















Figure 3. Survival curves, bacterial counts and SpeB expression phenotype following 
subcutaneous infection of humanized plasminogen transgenic mice (Tg+) and non-
transgenic control mice (Tg-) with S. pyogenes strain 5448 (WT) or the isogenic ∆speB 
mutant. (a) The virulence of 5448 is increased in transgenic mice compared with the non-
transgenic control. (b) The virulence of the ∆speB mutant was attenuated in both transgenic 
and control mice. (c) Bacterial counts in the bloodstream of Tg+ mice 72 h post-infection 
are significantly higher for 5448 compared with ∆speB. (d) Compared with the SpeB 
activity of 5448 colonies isolated from the inoculum, the 5448 Tg+ lesion isolates exhibit a 
varied SpeB-expression phenotype, while the 5448 Tg+ blood isolates have significantly 















Figure 4. Proposed model for group A streptococcal systemic disease initiation. (a) S. 
pyogenes M1T1 (blue) gain entry through the skin and a host innate immune response is 
initiated. (b) During the initial stages of infection, S. pyogenes M1T1 express SpeB to 
combat the host response. (c) Loss of SpeB activity in a sub-population of group A 
streptococci (green) leads to the accumulation of surface plasmin activity. (d) Transition of 
S. pyogenes M1T1 is facilitated by surface plasmin activity, resulting in systemic infection. 
